Stockreport

SELLAS To Present Data from Phase 2b Trial of NeuVax + Herceptin® at Upcoming European Society for Medical Oncology (ESMO) 2018 Meeting

SELLAS Life Sciences Group, Inc.  (SLS) 
Last sellas life sciences group, inc. earnings: 11/14 04:41 pm Check Earnings Report
PDF Oral Presentation of NeuVax + Herceptin in the Adjuvant Treatment of Triple-Negative Breast Cancer Conference Scheduled for October 19-23, 2018 in Munich, Germany NEW [Read more]